Previous 10 | Next 10 |
JENA, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the 11 th Annual SVB Leerink Healthcare Conference being held virtually ...
Regulatory discussions on Phase I program have been initiated First-in-human study expected to start in the second half of 2022 JENA, Germany, Jan. 10, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory t...
Presentation at J.P. Morgan Healthcare Conference on January 13 th Corporate presentation for H.C. Wainwright BioConnect Conference available online starting January 10 th Company to host virtual R&D Event on vilobelimab in Hidradenitis Suppurativa on February 3 rd...
Phase III study to include a new primary endpoint, the modified HiSCR New primary endpoint and Phase III trial design to be discussed in detail at virtual R&D event on February 3 rd Phase III program to focus on HS patients with active draining tunnels and will start enrol...
Today, we shine the spotlight on InflaRx, a small biotech concern based in Germany. The stock is deep in 'Busted IPO' territory even as the company has seen an increasing amount of news flow around it in recent months. A full investment analysis follows in the paragraphs below. ...
iSpecimen (NASDAQ:ISPC) +70% COVID-19 vaccine stocks surge on worries over new variant Allied Healthcare Products (NASDAQ:AHPI) +68%. Alpha Pro Tech (NYSE:APT) +24% Zoom Video and Peloton take off as new COVID variant revives stay-at-home trade Valneva SE (NASDAQ:VALN) +18...
InflaRx's (NASDAQ:IFRX) vilobelimab for ANCA-associated vasculitis achieved its primary objective in a mid-stage trial. That objective was demonstrating comparable response of vilobelimab to standard of care, while significantly reducing the need for glucocorticoid treatment. Result...
Proof of concept established for potential of vilobelimab to reduce use of corticosteroids in AAV patients: vilobelimab demonstrated comparable efficacy to standard of care Use of vilobelimab instead of glucocorticoids led to a substantially lower observed glucocorticoid toxicity ...
Last week was mixed for the penny stocks and higher-priced ones alike. While there were plenty of trends to follow, some continued gaining steam heading into the middle of November. Sure, you’ve got things like metaverse stocks, short squeeze penny stocks , and your typical low f...
JENA, Germany, Nov. 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, wi...
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...